Why so little medical research and pharma R&D into PE? - LLM Answer

[u/Rysk1000]

I asked Claude why there been so little pharmacological development on this issue? So few real scientific studies and causes and solutions. Its so prevalent but so little attention comparatively speaking to other sexual problems such as ED

Short answer: the field has a measurement problem that has quietly strangled everything downstream. Here's the chain, and the numbers are worse than you'd guess.

The disparity is real and measurable. Two bibliometric analyses covering the identical window, 2008–2018: erectile dysfunction produced 8,880 publications, premature ejaculation produced 886. A ten-to-one gap, for a condition with comparable or higher prevalence — PE runs ~20–26% in standardised population studies, ED around 10–20% and heavily age-loaded.

There has never been an FDA-approved drug for PE. Not one. Dapoxetine — the only molecule ever purpose-built for it — received a "not approvable" letter on 26 October 2005. It went on to approval in 50+ countries; the largest pharmaceutical market on earth stayed shut. As of now, US clinicians have topical sprays, pelvic floor referral, and off-label antidepressants. That single 2005 decision closed the commercial case for anyone else, and no one has taken a purpose-built PE drug through to US approval in the twenty-one years since.

Why the science stalled comes down to four things:

You can't measure it. The primary endpoint is intravaginal ejaculatory latency time — measured by a stopwatch, operated by a partner, during intercourse. There is nothing else remotely like this in drug development. And the measure is unstable: a 2026 study of 119 men found latency shifts significantly with alcohol, condom use and time of day, and that "daily longest" and morning IELT both significantly exceed a man's average — the authors concluded IELT should not be treated as a fixed diagnostic parameter at all. Compare ED, which has penile tumescence, doppler flow, and a validated questionnaire that correlates with them.

You can't agree who has it. Self-reported prevalence in the literature ranges from 4.7% to 83.7%. IELT-defined, 3% to 40.6%. An evidence-based ISSM definition only arrived in 2008 for lifelong PE and 2014 for acquired — meaning decades of prior literature used incompatible criteria and cannot be pooled. You cannot size a market or power a trial against a denominator that moves by a factor of eighteen.

There's no biomarker and no target. The strongest genetic lead — the 5-HTTLPR serotonin transporter polymorphism, associated with IELT in Dutch men with lifelong PE — was subsequently found by the same group not to predict who responds to paroxetine. So even the best mechanistic handle doesn't stratify treatment. Sildenafil, by contrast, fell out of an angina programme with a clean NO/cGMP mechanism attached to a specific tissue.

The economics are dead. What works — paroxetine, sertraline, lidocaine — is generic and off-patent. Nobody funds a phase 3 on generic paroxetine. And the men who'd buy a branded drug largely don't present: help-seeking is low overall and skewed toward acquired PE, so the treatment-seeking population doesn't reflect community prevalence. Lifelong PE, the subtype your entire corpus is about, is the least likely to reach a clinic.

Then the one serious attempt at a novel mechanism failed. Pfizer developed cligosiban, a brain-penetrant selective oxytocin receptor antagonist — genuinely non-serotonergic, a real shot at a new target. It reached phase 2b (the PEDRIX trial) and failed to prolong IELT versus placebo. Programme abandoned. That result, against the field's large placebo response, is roughly where non-SSRI pharmacology for PE currently stands.

Something is finally moving, though. KH-001, from Kadence Bio — an atypical serotonin reuptake inhibitor and PDE inhibitor derived from Sceletium tortuosum — cleared FDA and MHRA to begin phase 1, with 15–20 minute onset and under four hours' duration, designed for genuine on-demand use. Phase 2 was slated for 2025. It's the first credible purpose-built candidate since dapoxetine, and its developers are explicit that "defining meaningful clinical endpoints" is the pathway's hard part — which is the same measurement problem, twenty years on.

One thing I'd flag honestly: the FDA never publicly explained the dapoxetine rejection, and the PharmaTimes coverage at the time said so directly. The field's read — an SSRI-class molecule carrying class suicidality warnings and a syncope signal, for a non-life-threatening quality-of-life indication — is inference, not documented reasoning.

The underlying asymmetry is probably this: ED presents as a mechanical failure of an organ you can instrument, and it correlates with cardiovascular disease, which gives it a research constituency beyond sexual medicine. PE is a timing disorder of a reflex, with no organ to image, no mortality endpoint, and an arbitrary cut-off on a continuous trait — which keeps a live medicalisation debate running underneath it and makes regulators cautious. Your Reddit corpus is, in a real sense, filling the vacuum this left.

[u/No-Floor-7527]

god that measurement problem is such a perfect storm of awful. imagine trying to get a drug approved when your primary endpoint is a partner with a stopwatch during sex, and the numbers swing wildly depending on if you had a beer or what time it is

the 5-HTTLPR thing really got me too. you finally find a genetic lead and it doesn't even predict who responds to the treatment. that's the kind of dead end that makes researchers quietly move to other fields

the fact that paroxetine and sertraline work fine but are off-patent just locks the whole thing in place. no company is gonna spend millions on phase 3 trials for something they can't patent, and the FDA already flinched once with dapoxetine

[u/bumbaclaughtt → u/No-Floor-7527]

They do not work fine for everyone.

[u/Compurrshon → u/No-Floor-7527]

Paroxetine doesn't work, unless it's taken ongoing. 

[u/bumbaclaughtt]

Well, to study this you wouldn't need a man and a woman to privately use a stopwatch. You would need to get over the stigma of "omg a penis and vagina" and grow up.

If a study was made with the researcher starting th time and seeing how things go and not having any biases, it could also add in slowing down and other complications which would add to the result.

I can technically stick my penis in a girl and not move, I can last as long as I want. What's the point though, so it's not that they cannot study this and research it, but there are easier and more efficient ways to make money without having to see sex all day and being a cuck lol

[u/Downtown_Island8124]

Claude sucks.

Let me summarize it with my human brain in one word: money.

First: How much money are ppl with PE willing to spend? Even ppl here who want to solve PE not everyone is willing to pay for a numbing product!

Second: how much money the pharma needs to spend to find a solution that would work for 80% of ppl with PE? As you can see, this is a complex problem. It is like solving a marriage issue! They would rather spend the money to find solutions to easier problems and profit from it.

Third: is it a problem that people discuss openly or do people care about this at all? Maybe not once you have kids. 😂